ArticleCureus2026
Steroid-Refractory Warm Autoimmune Haemolytic Anaemia Complicating Ulcerative Colitis in Pregnancy: A Case Report and Management Considerations.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune haemolytic anaemia (AIHA) arising in pregnancy is an exceptionally rare condition, and its concurrence with active ulcerative colitis (UC) presents considerable diagnostic and therapeutic complexity. We describe a 30-year-old primigravida who presented at 12 weeks' gestation with severe symptomatic anaemia (haemoglobin 4.4 g/dL), serologically confirmed warm AIHA (strongly positive direct antiglobulin test, IgG-mediated), and concurrent gastrointestinal haemorrhage attributable to an acute flare of UC. High-dose corticosteroid therapy failed to achieve a durable response, and the patient developed steroid-refractory disease characterised by recurrent haemolytic episodes necessitating repeated red cell transfusion. Infliximab was initiated for refractory colitis but was rendered ineffective by the development of anti-drug antibodies. Subsequent therapeutic escalation comprised intravenous immunoglobulin, rituximab, azathioprine, and darbepoetin alfa; vedolizumab was later introduced to achieve intestinal remission. Following rituximab administration, haemoglobin stabilised progressively, transfusion dependence resolved, and haemolysis indices normalised, notwithstanding persistent direct antiglobulin test positivity. By 32 weeks' gestation, haemoglobin had risen to above 10 g/dL with complete clinical remission of haemolysis. Delivery was expedited at 35 weeks' gestation by caesarean section owing to superimposed pre-eclampsia; no haemolytic relapse was observed in the peripartum period. The neonate was admitted to the neonatal intensive care unit for three weeks due to respiratory distress syndrome but demonstrated no evidence of haemolysis or neonatal alloimmune or autoimmune complications. This case illustrates that UC-associated, steroid-refractory AIHA in pregnancy, whilst rare, is amenable to successful management through timely escalation to biologic and immunosuppressive therapy, judicious use of erythropoiesis-stimulating agents to minimise transfusion burden, and close multidisciplinary collaboration between haematology, gastroenterology, and maternal-foetal medicine, with favourable maternal and neonatal outcomes achievable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.